Parasites & vectors · 2026
Efficacy of Simparica Trio® (sarolaner, moxidectin, and pyrantel chewable tablets) against circulating microfilariae in dogs infected with Dirofilaria immitis.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Packianathan Raj, Ahn Kyu Sung, Shin SungShik, Cho Hyeonjo, Kim Jihae, Rodriguez Jessica, Geurden Thomas
Аннотация
BACKGROUND: Canine heartworm disease remains a global threat despite the availability of multiple preventive options, a challenge compounded by the emergence of macrocyclic lactone-resistant heartworm strains, especially in the USA. Circulating microfilariae play a pivotal role in heartworm transmission, serving as a continuous infection reservoir for mosquito vectors. Therefore, targeting this life cycle stage is critical in the framework of a comprehensive and multimodal heartworm prevention strategy.
METHODS: A randomised, blinded, negative-controlled laboratory study evaluated the efficacy of Simparica Trio® (Zoetis Inc., Parsippany, NJ, USA), containing a minimum dosage of 1.2 mg/kg sarolaner, 24 µg/kg moxidectin, and 5 mg/kg pyrantel, against circulating microfilariae. Dogs naturally infected with heartworm and harbouring circulating microfilariae were enrolled in the study. Twelve dogs received a single treatment with Simparica Trio as per recommended label dosage, and efficacy was compared with an untreated control group of 10 dogs weekly for 28 days.
RESULTS: There were no adverse events recorded in this study. Following a single oral dose of Simparica Trio, a significant reduction in microfilaria counts in the Simparica Trio-treated group relative to the control group was first detected within 7 days (P < 0.0001), resulting in an efficacy of 99.9% (98.9%) based on geometric (arithmetic) means. The efficacy remained at least 99.9% (≥ 99.5%) based on geometric (arithmetic) means for 28 days (P < 0.0001).
CONCLUSIONS: A single oral dose of Simparica Trio was highly effective against circulating microfilariae in naturally infected dogs with D. immitis for 1 month. Combining its effects on migrating L4 stages and circulating microfilariae coupled with mosquito killing, Simparica Trio offers a multimodal, holistic, integrated solution to heartworm prevention in dogs.
METHODS: A randomised, blinded, negative-controlled laboratory study evaluated the efficacy of Simparica Trio® (Zoetis Inc., Parsippany, NJ, USA), containing a minimum dosage of 1.2 mg/kg sarolaner, 24 µg/kg moxidectin, and 5 mg/kg pyrantel, against circulating microfilariae. Dogs naturally infected with heartworm and harbouring circulating microfilariae were enrolled in the study. Twelve dogs received a single treatment with Simparica Trio as per recommended label dosage, and efficacy was compared with an untreated control group of 10 dogs weekly for 28 days.
RESULTS: There were no adverse events recorded in this study. Following a single oral dose of Simparica Trio, a significant reduction in microfilaria counts in the Simparica Trio-treated group relative to the control group was first detected within 7 days (P < 0.0001), resulting in an efficacy of 99.9% (98.9%) based on geometric (arithmetic) means. The efficacy remained at least 99.9% (≥ 99.5%) based on geometric (arithmetic) means for 28 days (P < 0.0001).
CONCLUSIONS: A single oral dose of Simparica Trio was highly effective against circulating microfilariae in naturally infected dogs with D. immitis for 1 month. Combining its effects on migrating L4 stages and circulating microfilariae coupled with mosquito killing, Simparica Trio offers a multimodal, holistic, integrated solution to heartworm prevention in dogs.